Herren Wu is Senior Vice President, Research & Development and Global Head of Antibody Discovery and Protein Engineering (ADPE) at AstraZeneca.

Herren founded the Department of Antibody Discovery and Protein Engineering in January 2002, when he joined MedImmune as Director. He was promoted to Senior Director in 2004 and Vice-President in 2006. He was also the founding department head for Biosuperiors R&D and led this organisation for three years (2010-2013).

During his tenure, Herren has successfully integrated ADPE platforms across all sites following the MedImmune/Cambridge Antibody Technology (CAT) merger. Under his leadership, ADPE developed many proprietary cutting-edge technology platforms, including half-life extension technology (YTE), bi-specifics/multi-specifics, protein scaffolds, antibody-drug conjugates, Blood-Brain-Barrier technology, peptide therapeutics, phenotypic screening and most recently mass-spec proteomics and non-natural amino acid technology.

In 2006, Herren received the Senior Technology Fellow Emerald Honors award. He is also an inventor on 43 granted patents and 50 patent applications related to antibody/protein therapeutics and technologies. This is in addition to more than 60 manuscript publications.

Herren received his bachelor’s degree in Chemistry from the National Taiwan University and his doctorate in Molecular and Cellular Biology from the University of Massachusetts, Amherst. He completed his postdoctoral training at The Scripps Research Institute in La Jolla, California.

  Extending the half-life of antibodies


The YTE leap in technology


Build and lead Biosuperiors R&D from 2010-2013


Initiate and lead the next-wave biologics technology strategy since 2013


Initiate and lead the development of non-mAb technologies such as bi-specifics, protein scaffold, peptides, antibody drug conjugates, BBB technology, Fc engineering

  Featured publications

Oligospecific antibodies for simultaneous targeting

The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. Dimasi N1, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, Kiener PA, Wu H. J. Mol. Biol. 2009. 393(3):672-92

IgG1 enhanced binding to FcRn

Properties of human IgG1s engineered for enhanced binding to FcRn. Dall'Acqua WF, Kiener PA, Wu H. J. Biol. Chem. 2006: 281(33):23514-24

Building zinc fingers

Building zinc fingers by selection: towards a therapeutic application.Wu H, Yang WP, Barbas CF 3rd. Proc. Natl. Acad. Sci. USA.1995; 92(2):344-8.


Senior Technology Fellow Emerald Honors award, 2006


MedImmune Science Excellence Special award for YTE technology, 2011


Who’s Who in Science and Engineering, 2000

Unlike academic labs where professors can work on disease mechanisms for decades but they rarely have a chance to validate their hypotheses in humans by developing drugs targeting such mechanisms, we have that opportunity at MedImmune.

Herren Wu